ReviewFrontiers in endocrinology2026
Ovarian intelligence: AI applications leveraging AMH and inhibin B.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence is transforming reproductive medicine by enabling more nuanced and personalized interpretation of key biomarkers such as anti-Müllerian hormone (AMH) and inhibin B. While AMH is widely adopted for assessing ovarian reserve, inhibin B-an follicle-stimulating hormone (FSH)-dependent marker of follicular activity-has been historically underutilized due to its dynamic nature and lack of standardized assays. In this review, we explore how AI-driven tools can integrate these hormonal signals to improve clinical decision-making. We highlight three representative models: OvaRePred (also known as HerTempo), which predicts ovarian reserve and perimenopausal timing; PCOSt, which enables early screening and phenotyping of polycystic ovary syndrome; and POvaStim, which personalizes gonadotropin dosing by modeling ovarian sensitivity. Collectively, these tools offer new possibilities for individualized fertility management and may help shift reproductive care from reactive treatment toward proactive, data-informed health planning. We also discuss emerging innovations such as cross-platform assay harmonization, point-of-care hormone testing, and longitudinal biomarker modeling. Looking ahead, integration with nutritional interventions, wearable technologies, and genetic or immunologic data could extend these tools beyond assisted reproduction-supporting a broader, AI-enabled ecosystem for women's lifelong health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.